Louisiana State University

LSU Digital Commons
Faculty Publications

School of Animal Sciences

10-15-2013

AMP-activated protein kinase mediates myogenin expression and
myogenesis via histone deacetylase 5
Xing Fu
Washington State University Pullman

Jun Xing Zhao
College of Animal Science and Veterinary Medicine

Junfang Liang
Washington State University Pullman

Mei Jun Zhu
Washington State University Pullman

Marc Foretz
Washington State University Pullman

See next page for additional authors

Follow this and additional works at: https://digitalcommons.lsu.edu/animalsciences_pubs

Recommended Citation
Fu, X., Zhao, J., Liang, J., Zhu, M., Foretz, M., Viollet, B., & Du, M. (2013). AMP-activated protein kinase
mediates myogenin expression and myogenesis via histone deacetylase 5. American Journal of
Physiology - Cell Physiology, 305 (8) https://doi.org/10.1152/ajpcell.00124.2013

This Article is brought to you for free and open access by the School of Animal Sciences at LSU Digital Commons.
It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital Commons.
For more information, please contact ir@lsu.edu.

Authors
Xing Fu, Jun Xing Zhao, Junfang Liang, Mei Jun Zhu, Marc Foretz, Benoit Viollet, and Min Du

This article is available at LSU Digital Commons: https://digitalcommons.lsu.edu/animalsciences_pubs/623

Am J Physiol Cell Physiol 305: C887–C895, 2013.
First published August 7, 2013; doi:10.1152/ajpcell.00124.2013.

AMP-activated protein kinase mediates myogenin expression and myogenesis
via histone deacetylase 5
Xing Fu,1* Jun-Xing Zhao,2* Junfang Liang,1 Mei-Jun Zhu,3 Marc Foretz,3,4,5 Benoit Viollet,4,5,6
and Min Du1
1

Department of Animal Sciences, Washington State University, Pullman, Washington; 2College of Animal Science and
Veterinary Medicine, Shanxi Agriculture University, Taigu, Shanxi, China; 3School of Food Sciences, Washington State
University, Pullman, Wyoming; 4Institut National de la Santé et de la Recherche Médicale U1016, Institut Cochin, Paris,
France; 5Université Paris Descartes, Sorbonne Paris Cité, Paris, France; and 6Centre National de la Recherche Scientifique
Unité Mixte de Recherche 8104, Paris, France
Submitted 2 May 2013; accepted in final form 5 August 2013

Fu X, Zhao JX, Liang J, Zhu MJ, Foretz M, Viollet B, Du M.
AMP-activated protein kinase mediates myogenin expression and myogenesis via histone deacetylase 5. Am J Physiol Cell Physiol 305: C887–C895,
2013. First published August 7, 2013; doi:10.1152/ajpcell.00124.2013.—
There is a global epidemic of obesity, and obesity is known to inhibit
AMP-activated protein kinase (AMPK) activity and impairs myogenesis. Myogenin mediates the fusion of myoblasts into myotubes, a
critical step in myogenesis. We observed that inhibition of AMPK␣1
downregulates myogenin expression and myogenesis, but the underlying mechanisms are unclear. We postulated that AMPK regulates
myogenin expression through phosphorlytion of histone deacetylase 5
(HDAC5). In C2C12 cells, HDAC5 knockdown increased while
HDAC5 stablization by MC1568 reduced myogenin expression. Consistently, using luciferase assay, we observed that myogenin promoter
activity was negatively regulated by HDAC5. Using RNA interference and primary myoblasts prepared from wild-type and AMPK␣1
knockout mice, we further demonstrate that AMPK␣1 regulates
HDAC5 phosphorylation at Ser 259 and 498. Mutation of these two
Ser to Ala in HDAC5 abolished the regulatory role of AMPK␣1 on
myogenin expression, clearly showing the necessity of these phosphorylation sites in mediating myogenin expression. In aggregate,
these data show that AMPK inhibition downregulates myogenin
transcription and myogenesis through phosphorylation of HDAC5,
mediated mainly by AMPK␣1. These data demonstrate that AMPK is
a key molecular target for promoting myogenesis and muscular
regeneration. Because drugs activating AMPK activity, such as metformin, are widely available, our finding has critical clinical implications to ensure proper muscle development and regeneration in obese
subjects and under other pathophysiological conditions where AMPK
activity is attenuated.
AMPK; histone deacetylase; myogenin; myogenesis; obesity; phosphorylation
SKELETAL MUSCLE, WHICH COMPRISES ⬃40% of the body mass of
adults, is the main peripheral tissue responsive to insulin
stimulated uptake of glucose (21) and critical in the development of type 2 diabetes (23). Skeletal muscle hyperplasia
occurs during the fetal stage while postnatal growth is primary
due to hypertrophy, both of which involve extensive myogenesis. Downregulation of myogenesis during the fetal stage
permanently reduces the number of muscle fibers in later life,
reducing muscle mass and contraction force (1, 3, 15). Con-
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sistently, attenuated myogenic differentiation and fusion of
satellite cells lead to muscular atrophy, impairing normal
muscular functions (2, 6, 10).
Obesity is increasing at an alarming pace with a current
obesity rate at ⬎30% and another 30% overweight in the
United States (12). It has been well demonstrated that obesity
and its associated chronic inflammation inhibit AMP-activated
protein kinase (AMPK) activity (9, 11, 20, 41). Our previous
studies show that low AMPK activity is correlated with attenuated myogenic differentiation during early muscle development (43, 46, 49). In addition, AMPK constitutively active
mutation in Rendement Napole (RN) pigs is associated with
enhanced muscle growth in this pig breed (29, 32). These data
show the positive association between AMPK and myogenesis,
but the causal relationship remains to be established. AMPK is
a heterotrimeric enzyme, composed of ␣-, ␤-, and ␥-subunits,
which plays an important role in energy metabolism (16, 19,
36). The catalytic ␣-subunit of AMPK has two isoforms, ␣1
and ␣2, which display differential expression during myogenic
cell differentiation (31). Knockout of either ␣1- or ␣2-subunit
results in visually normal mice, but knockout of both ␣1and ␣2-subunits is lethal around embryonic day 9.5 (45),
showing that ␣1 and ␣2 have compensatory roles in regulating fetal growth and development. Currently, there is no
direct evidence detailing the AMPK isoform-specific role in
myogenesis.
Cell differentiation and tissue development are controlled by
epigenetic modifications, including histone and DNA modifications (33, 38). Histone acetylation activates gene expression
(24, 28), which is regulated by histone acetyltransferase and
histone deacetylase (HDAC; Ref. 40). HDAC5 belongs to the
class IIa HDAC family and acts as a conserved transcriptional
repressor through interaction with myocyte enhancer factor-2
(MEF2) (4). The activity of HDAC5 is mainly regulated
through phosphorylation by several kinases (14, 27, 48). Myogenin is necessary for myoblast fusion into myotubes, a critical
step in myogenesis (8, 37). The myogenin promoter contains a
MEF2 binding site (17), which prompted us to hypothesize that
AMPK activity is necessary for myogenesis through a process
mediated by HDAC5 and MEF2 and that an AMPK isoformspecific mechanism exists. Our data demonstrated that
AMPK␣1 but not AMPK␣2 stimulates myogenin expression
and myogenesis via phosphorylation of HDAC5 at Ser 259 and
498, which provides an important mechanisms linking AMPK
to myogenic differentiation.
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MATERIALS AND METHODS

Animal experiments. All animals were handled in accordance with
protocols approved by the Animal Use and Care Committees of
Washington State University (Permit No. 04158). Wild-type (WT)
C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor,
ME). AMPK␣1⫺/⫺ 129S2/SvPas [AMPK␣1 knockout (KO)] and
AMPK␣2⫺/⫺ C57BL/6 (AMPK␣2 KO) mice were generated as
previously described (18, 44).
Antibodies and chemicals. Antibodies against HDAC5 (no. 2082),
phospho-HDAC5 at Ser 259 (no. 3443), phospho-HDAC5 at Ser 498
(no. 3424), tag (no. 2368), mouse IgG (no. 7076), ␤-tubulin (no.
2146), histone H3K9 (no. 9649), goat anti-mouse Alexa Fluor 555
(no. 4409), goat anti-rabbit Alexa Fluor 488 (no. 4412), and goat
anti-rabbit Alexa Fluor 555 (no. 4413) antibodies were purchased
from Cell Signaling (Danvers, MA). Rabbit anti-desmin antibody
(ab15200) was purchased from Abcam (Cambridge, MA). Antimyogenin (F5D) and anti-myosin heavy chain (anti-MHC; MF20)
mouse monoclonal antibodies were obtained from the Developmental
Studies Hybridoma Bank (Iowa City, IA). IRDye 800CW goat antirabbit secondary antibody and IRDye 680 goat anti-mouse secondary
antibody were purchased from LI-COR Biosciences (Lincoln, NE).
Puromycin were purchased from Sigma (St. Louis, MO). MC1568
was purchased from Selleck (Houston, TX). pGL4 promoter luciferase plasmid was purchased from Promega (Madison, WI). Lipofectamine was purchased from Invitrogen (Carlsbad, CA).
Cell culture. Myogenic C2C12 cells were grown at 37°C with 5%
CO2 in DMEM supplemented with 10% FBS and 1% antibiotic
mixture. Primary myoblasts were extracted from neonatal mice following a procedure described previously with modifications (35).
Briefly, muscle from hindlimbs was minced and digested in DMEM
with collagenase D and Dispase II (Roche Diagnostics, Mannheim,
Germany) at 37°C for ⬃30 min. The slurry was then passed through
a 100-m cell strainer. Cells were collected by centrifuge at 350 g for
5 min. The cell pellet was then resuspended in F-10 with 20% FBS
and 1% antibiotic mixture. Primary myoblasts were seeded on collagen-coated plates and enriched by preplating. The purity of enriched
primary myoblasts was checked by FACS and immunocytochemistry
using anti-desmin antibody. When cells reached 100% confluence, the
culture medium was switched to DMEM supplemented with 2% horse
serum and 1% antibiotic mixture to induce myogenic differentiation.
Myogenin mRNA expression, myogenin protein content, and MHC
were analyzed at 2, 3, and 6 days after inducing myogenesis respectively.
Immunoblotting analyses. Immunoblotting analysis was performed
as previously described using an Odyssey Infrared Imaging System
(LI-COR Biosciences, Lincoln, NE; Ref. 48). Band density was
normalized to ␤-tubulin content.
Real-time quantitative PCR. Total RNA was extracted using Trizol
(Sigma) followed by DNase (NEB, Ipswich, MA) treatment, and
cDNA was synthesized using a reverse transcription kit (Bio-Rad,
Hercules, CA). Real-time quantitative PCR (RT-PCR) was carried out
using CFX RT-PCR detection system (Bio-Rad) with a SYBR Green
RT-PCR kit from Bio-Rad. The following cycle parameters were
used: 34 three-step cycles of 95°C, 20 s; 55°C, 20 s; and 72°C, 20 s.
Primer sequences and their respective PCR fragment lengths were as
follows: Myogenin (97 bp), forward 5=-GAGATCCTGCGCAGCGCCAT-3=, and reverse 5=-CCCCGCCTCTGTAGCGGAGA-3=; and
18S rRNA (110 bp), forward 5=-TGCTGTCCCTGTATGCCTCT-3=,
and reverse 5=-TGTAGCCACGCTCGGTCA-3=. After amplification,
a melting curve (0.01°C/s) was used to confirm product purity, and
agarose gel electrophoresis was performed to confirm that only a
single product of the right size was amplified. Relative mRNA content
was normalized to 18S rRNA content.
Construction of expression vector. The myogenin promoter fragment
containing the MEF2 binding site was amplified from mouse genomic
DNA using the following primers: forward 5=- CTAGCTAGCCGTC-

CGTCCAAGACAACCC-3=, and reverse 5=- CCGCTCGAGCAGGTCGGAAAAGGCTTGTT-3=. PCR products were subcloned between
Xhol and Nhel sites of the pGL4-promoter-luciferase plasmid. The
construct was verified by digestion with restriction enzymes and sequencing.
Transfection. Plasmid transfection of C2C12 was performed using
Lipofectamine according to the manufacturer’s instructions. Briefly,
12 h before transfection, cells were switched to medium without
antibiotics. Transfections were carried out when cells reached 95%
confluence, using a 1:3 ratio of DNA (g):Lipofectamine (l); medium was switched to DMEM medium containing 10% FBS and 1%
antibiotics 12 h following transfection. For short hairpin (sh)RNA
interference, AMPK␣1 shRNA, AMPK␣2 shRNA, HDAC5 shRNA,
and control shRNA (Santa Cruz Biotech, Santa Cruz, CA) were
delivered into cells, and transfected cells were selected with
puromycin (2 g/ml). For HDAC5 overexpression, C2C12 cells
were transfected with HDAC5 expression vectors, FLAG-HDAC5WT, FLAG-HDAC5-S259A, FLAG-HDAC5-S498A, and FLAGHDAC5-S259A/S498A (catalog no. 32213, 32214, 32215, and
32216; Addgene, Cambridge, MA). C2C12 cells transfected with
green fluorescent protein (GFP) expression vector and nontransfected C2C12 cells were used as controls.
Plasmid transfection of primary myoblasts was performed using
neon transfection system from Life Technologies (Grand Island, NY)
following the manufacturer’s suggested protocol with slight modifications. Briefly, 5 ⫻ 105 primary myoblasts were resuspended in 100
l resuspension buffer and mixed with 5 g of each plasmid. The
mixture was then loaded to the system. Transfection was performed
with the following parameters: pulse voltage (1,500 V), pulse width
(10 ms), and pulse number (3). Transfected primary myoblasts were
then cultured in F-10 with 20% FBS and 1% antibiotic mixture.
Luciferase reporter activity assay. To measure the transcriptional
activity of the myogenin promoter, C2C12 cells were transfected with
different expression vectors. Renilla luciferase vector (Promega, Madison, WI) was transfected as an internal control, and each transfection
assay was performed at least six times. An equal amount of plasmids
was used for all treatments. At 24 h following transfection, cells were
harvested, and luciferase activity was measured using a dual luciferase
assay kit (Promega) according to the manufacturer’s instructions. Data
from each experiment were normalized to the Renilla luciferase
activity (48).
FACS. Cells were fixed in 4% PFA for 10 min at 37°C, permeabilized in ice-cold methanol for 30 min, and washed in PBS with 1%
BSA. Then, 5 ⫻ 105 cells in PBS with 1% BSA were stained with
rabbit anti-desmin primary antibody for 1 h, washed, and stained with
goat anti-rabbit Alexa Fluor 555 secondary antibody for 30 min.
Stained cells were sorted on FACSaria (BD Biosciences, San Jose,
CA) and analyzed by FlowJo (Treestar, San Carlos, CA).
Immunocytochemical staining. Cells grown on coverslips were
fixed in 4% paraformaldehyde for 10 min, permeabilized with ice-cold
methanol for 5 min, quenched with 0.1% sodium borohydride for 5
min, and incubated with anti-MHC, anti-desmin, or mouse IgG
(1:100) at 4°C overnight. Fluorescent secondary antibody (1:1,000)
was then added, and stained cells were incubated at room temperature
for 1 h. Fluorescence was examined using a Leica inverted microscope (48).
Muscle fiber counting, muscle fiber area measure, muscle mass
measure, and head-to-tail length measure. Two-month-old WT mice,
AMPK␣1 KO mice, and AMPK␣2 KO mice were killed using CO2.
Body weight and head-to-tail length were measured. Tibialis anteria
(TA) muscle were weighed. Soleus muscle were isolated, fixed in 4%
paraformaldehyde, and embedded in paraffin. Embedded tissue were
sectioned (6-m thick) and stained with hematoxylin and eosin. Cross
sections with similar distance to the distal end of muscle were
analyzed using Image pro plus (Media Cybernetics, Rockville, MD) to
determine muscle fiber number and area.
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Statistics. For all studies, at least three independent experiments were
conducted. All data are expressed as means ⫾ SE. Data were analyzed
using the general linear model of SAS (SAS Institute, Cary, NC), and
Tukey’s Studentized range test was used to determine significance of
differences among means. P ⬍ 0.05 was considered significant.
RESULTS

HDAC5 regulates myogenin expression and myogenesis.
HDAC5 regulates gene transcription through interaction with
MEF2 (22), and a conserved MEF2 binding site on the myogenin promoter has been identified (17). To investigate
whether HDAC5 regulates myogenin mRNA transcription, we
used HDAC5 shRNA to knock down endogenous HDAC5. We
found that HDAC5 knockdown increased myogenin mRNA
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levels (Fig. 1A). Myogenin and MHC protein levels were also
increased as was H3K9 acetylation (Fig. 1B). Immunocytochemical staining further confirmed that more myotubes
were formed by myocytes following HDAC5 knockdown
compared with control shRNA transfected cells (Fig. 1C).
To further investigate the role of HDAC5 on myogenin
expression, HDAC5 was then overexpressed in C2C12 cells.
As expected, myogenin protein level was decreased pronouncedly (Fig. 1D).
C2C12 cells were treated with MC1568 (5 M), a specific class
II HDAC inhibitor, which stabilizes the repressor structure of
HDAC5 (30). The myogenin mRNA level was decreased dramatically by the addition of MC1568 (Fig. 2A). In addition, MC1568
treatment decreased myogenin and MHC protein levels (Fig. 2B).

Fig. 1. Histone deacetylase 5 (HDAC5) regulated myogenin expression and myogenesis. A: myogenin mRNA content in C2C12 cells following HDAC5 knockdown.
B: HDAC5, H3K9, myogenin, and myosin heavy chain (MHC) protein content in C2C12 cells following HDAC5 knockdown. C: MHC immunocytochemical staining
of myotubes formed by C2C12 transfected with control short hairpin (sh)RNA and HDAC5 shRNA. D: myogenin protein level in C2C12 following HDAC5
overexpression. GFP, green fluorescent protein. *P ⬍ 0.05 vs. control; **P ⬍ 0.01 vs. control; ***P ⬍ 0.0001 vs. control; means ⫾ SE; n ⱖ 3.
AJP-Cell Physiol • doi:10.1152/ajpcell.00124.2013 • www.ajpcell.org
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Fig. 2. HDAC5 stabilization by MC1568 reduced myogenin expression and myogenesis. C2C12 cells in myogenic differentiation medium supplemented with
MC1568 (5 M) or vehicle (PBS). A: myogenin mRNA content analyzed by RT-PCR. B: myogenin and MHC contents analyzed by immunoblotting. C: MHC
immunocytochemical staining of myotubes. *P ⬍ 0.05 vs. control; ***P ⬍ 0.0001 vs. control; means ⫾ SE; n ⱖ 3.

As expected, MC1568 also decreased the number of mature
myotubes compared with the control group (Fig. 2C).
The gene-specific deacetylation of HDAC5 is mediated by
MEF2. To determine if HDAC5 regulates the transcriptional
activity of the myogenin promoter, we cloned the myogenin

promoter containing the MEF2 binding site into pGL4 luciferase vector to construct a myogenin promoter-driven luciferase reporter vector. C2C12 cells transfected with the
myogenin promoter-luciferase vector were cotransfected with
the HDAC5 expression vector or GFP vector. Cells receiving

Fig. 3. HDAC5 regulated myogenin promoter activity. A: luciferase activity of C2C12 cells transfected with myogenin promoter reporter, together with or without
HDAC5 vector. B: luciferase activity of C2C12 cells with HDAC5 knockdown or control shRNA transfection plus myogenin promoter reporter. *P ⬍ 0.05 vs.
control; **P ⬍ 0.01 vs. control; means ⫾ SE; n ⱖ 3.
AJP-Cell Physiol • doi:10.1152/ajpcell.00124.2013 • www.ajpcell.org
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the myogenin promoter-luciferase vector and GFP vector expressed higher luciferase activity than cells receiving myogenin promoter-luciferase vector and HDAC5 vector (Fig. 3A).
Knockdown of endogenous HDAC5 by HDAC5 shRNA resulted in elevated luciferase activity (Fig. 3B), demonstrating
that HDAC5 downregulates myogenin expression and myogenesis.
AMPK␣1 phosphorylates HDAC5, necessary for mediating
myogenin expression. To test the effects of reduced AMPK
activity on phosphorylation of HDAC5, we isolated myoblasts
from WT and AMPK␣1 KO mice and tested the phophorylation level of HDAC5 Ser 259 and HDAC5 Ser 498, which are
known to be phosphorylated by AMPK (26). We found that
the phosphorylation of both HDAC5 Ser 259 and Ser 498 were
reduced in AMPK␣1 KO myoblasts (Fig. 4A). As expected the
myogenin protein level was lower in TA muscle isolated from
2-mo-old AMPK␣1 KO mice than that from 2-mo-old WT
mice (Fig. 4B). WT and AMPK␣1 KO primary myoblasts were
isolated, enriched, and tested for purity by FACS and ICC
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using anti-desmin antibody (Fig. 4, C and D). Enriched myoblasts were then induced for myogenic differentiation. We
found that the myotube formation of AMPK␣1 KO myoblasts
was greatly reduced (Fig. 4E). To further test whether AMPK
mediates myogenesis through HDAC5 in an isoform-specific
manner, we transfected control cells and AMPK␣1 knockdown
cells with vectors expressing WT HDAC5, HDAC5 with Ser
259 mutated to Ala, or HDAC5 with Ser 498 mutated to Ala;
Ser 259 and Ser 498 are two putative phosphorylation sites by
AMPK. When transfected with WT HDAC5, AMPK␣1 knockdown was associated with a lower myogenin content compared
with the control group (Fig. 4F). In contrast, transfection with
mutant HDAC5s blocked the downregulation of myogenin
expression by AMPK knockdown, clearly showing the necessity of these phosphorylation sites in AMPK-regulated myogenin expression (Fig. 4G).
We further analyzed myogenin promoter-mediated luciferase activity. HDAC5 suppressed the transcriptional activity of the myogenin promoter in AMPK␣1 knockdown cells;

Fig. 4. AMP-activated protein kinase (AMPK)␣1 enhances myogenesis through phosphorylating HDAC5 at Ser 259 and 498. A: levels of HDAC5
phosphorylated at Ser 259 (S259) and Ser 498 (S259) in wild-type (WT) and AMPK␣1 knockout (KO) myoblasts. B: myogenin protein level in tibialis anteria
(TA) muscle isolated from 2-mo-old WT and AMPK␣1 KO mice. C–D: enriched myoblasts were tested for purity by FACS (C) and immunocytochemistry (D)
using anti-desmin antibody. E: MHC immunocytochemical staining of myotubes formed by WT and AMPK␣1 KO myoblasts. F: myogenin and MHC levels
in control, C2C12, and C2C12 cells with AMPK␣1 knockdown and transfected with WT HDAC5. G: myogenin and MHC levels in control, C2C12, and C2C12
cells with AMPK␣1 knockdown and transfected with HDAC5 S259A (Ser 259 to Ala) and HDAC5 S498A (Ser 498 to Ala). *P ⬍ 0.05 vs. control; **P ⬍ 0.01
vs. control; ***P ⬍ 0.0001 vs. control; means ⫾ SE; n ⱖ 3.
AJP-Cell Physiol • doi:10.1152/ajpcell.00124.2013 • www.ajpcell.org
Downloaded from journals.physiology.org/journal/ajpcell at LSU Louisiana State Univ (130.039.060.113) on January 14, 2022.
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this effect was absent in cells transfected with the HDAC5
mutants, further demonstrating that AMPK regulates myogenin
expression through phosphorylation of HDAC5 (Fig. 5A).
We also analyzed myogenin mRNA expression. Consistently, AMPK␣1 knockdown cells transfected with HDAC5
exhibited reduced myogenin mRNA contents; however, cells
transfected with either HDAC5 mutant showed no change in
myogenin mRNA contents (Fig. 5B). In aggregate, these data
show that AMPK inhibition downregulates myogenin transcription and myogenesis through HDAC5 in C2C12 cells.
Enriched primary myoblasts were further transfected with myogenin promoter-luciferase vector together with WT HDAC5,
HDAC5 S259A, HDAC5 S498A, or HDAC5 with both sites
mutated (HDAC5 DM). WT HDAC5 significantly suppressed
the activity of myogenin promoter in AMPK␣1 KO primary myoblasts compared with WT primary myoblasts
(P ⬍ 0.01). HDAC5 S259A suppressed the activity of myogenin promoter in AMPK␣1 KO primary myoblasts but to a
lesser extent (P ⬍ 0.05). HDAC5 S498A caused a slight but
not significant reduction in the activity of myogenin promoter.
The HDAC5 double mutant failed to achieve any suppression

in the activity of myogenin promoter compared with WT and
AMPK␣1 KO primary myoblasts (Fig. 5C). These data further
confirmed that AMPK regulates HDAC5 through phosphorylation at S259 and S498 and these phosphorylations induce
myogenin expression.
AMPK␣1 KO mice had reduced muscle mass, less muscle
fiber number and smaller muscle fiber diameter. Our in vitro
studies have clearly established that AMPK␣1 KO attenuated
myogenesis via phosphorylation of HDAC5. If this notion is
correct, we expect to see that AMPK␣1 KO mice has reduced
muscle mass, less muscle fibers, and small muscle fiber size
compared with those of WT mice. Indeed, the TA muscle in
AMPK␣1 KO mice was significantly smaller than that in WT
mice. It should be noticed that the reduced muscle mass was
due to smaller muscle diameter rather than reduced muscle
length (Fig. 6A). The body weight of AMPK␣1 KO mice was
also found to be smaller than that of WT mice but no difference
in head-to-tail length, indicating that the reduced body weight
was mainly due to reduced muscle mass (Fig. 6B). As expected, the total number of fibers in the whole soleus muscle
cross section of AMPK␣1 KO mice was ⬃25% less than that

Fig. 5. Mutation on HDAC5 phosphorylation sites abolished the effect of AMPK on myogenin promoter activity. A: C2C12 cells were transfected with pGL4
myogenin ⫹ luciferase vector, either scramble or AMPK␣1 ShRNA, together with HDAC5, HDAC5 S259A, or HDAC5 S498A. Myogenin promoter activity
was monitored by luciferase activity. B: C2C12 cells were transfected with either scramble or AMPK␣1 ShRNA, together with HDAC5, HDAC5 S259A, or
HDAC5 S498A. Myogenin mRNA contents were tested by RT PCR. C: WT and AMPK␣1 KO primary myoblasts were transfected with HDAC5, HDAC5
S259A, HDAC5 S498A, or HDAC5 DM (with both Ser 259 and Ser 498 mutated to Ala), together with pGL4 myogenin promoter reporter vector. Luciferase
activity was analyzed. *P ⬍ 0.05 vs. control; **P ⬍ 0.01 vs. control; means ⫾ SE; n ⱖ 3.
AJP-Cell Physiol • doi:10.1152/ajpcell.00124.2013 • www.ajpcell.org
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Fig. 6. Effects of AMPK KO on muscle mass, muscle fiber number, body weight and head-to-tail length of mice. A: weight of TA muscle of WT and AMPK␣1
KO mice. B: body weight and head-to-tail length of WT and AMPK␣1 KO mice. C: hematoxylin and eosin staining of soleus muscle cross sections of WT mice,
AMPK␣1 KO mice and AMPK␣2 KO mice. C=: muscle fiber numbers in soleus muscle from WT mice, AMPK␣1 KO mice and AMPK␣2 KO mice. C⬙: average
area of muscle fibers in soleus muscle from WT mice, AMPK␣1 KO mice, and AMPK␣2 KO mice. *P ⬍ 0.05 vs. control; **P ⬍ 0.01 vs. control; means ⫾
SE; n ⱖ 3.

of WT mice, and muscle fibers in AMPK␣1 KO mice were
⬃20% smaller in diameter than muscle fibers in WT mice (Fig.
6C). However, an increased muscle fiber diameter (Fig. 6C)
and muscle mass (data not shown) was observed in AMPK␣2
KO mice, albeit no change in muscle fiber number, which
further suggests an AMPK␣1-specific role in myogenesis.
DISCUSSION

Obesity and T2D are closely linked metabolic complications, both of which are increasing at alarming rates (34).
Pathophysiological changes such as obesity and chronic inflammation are known to inhibit, rather than activate, AMPK
(41), suggesting that inhibition, rather than activation, is more
relevant to the pathophysiological roles of AMPK (7, 47).
AMPK is phosphorylated by a constitutively active kinase,
LKB1, which suggests that dephosphorylation rather than
phosphorylation may be the main mechanism for regulating
AMPK activity (39). In our previous studies, we observed that
low AMPK activity correlated with impaired myogenesis (50),
despite of undefined mechanisms.
To explore, we analyzed the structure of myogenin promoter
and found a conserved MEF2 binding site on the myogenin
promoter (17). It is well established that HDAC5 interacts with
MEF2 to regulate gene expression (24, 25). We asked whether
HDAC5 was involved in the regulation of myogenin expression. Indeed, HDAC5 knockdown increased H3K9 acetylation,

which was associated with enhanced myogenin expression and
myogenesis. We also treated C2C12 cells with MC1568, which
stabilizes the repressor structure of HDAC5 (30); consistently,
the myogenin level and myogenesis were decreased. In addition, overexpression of HDAC5 in C2C12 reduced myogenin
content. In combination, these data indicate that HDAC5 negatively regulates myogenin transcription and myogenesis.
To further determine if HDAC5 directly regulates the transcriptional activity of the myogenin promoter, we cloned the
myogenin promoter into pGL4 luciferase vector to construct a
myogenin promoter-driven luciferase reporter. In line with
above data, HDAC5 negatively regulates the transcriptional
activity of myogenin promoter.
Phosphorylation of HDAC5 by protein kinases leads to its
translocation from the nucleus to the cytoplasm. This represents a conserved mechanism by which HDAC class II family
members regulate gene transcription (13). Our previous study
showed that AMPK phosphorylates HDAC5 at Ser 259 and
498, promoting its nuclear translocation to induce ␤-catenin
expression (48). Consistently, experiment showed that phosphorylation of HDAC5 is reduced in AMPK␣1 KO myoblasts.
We then tested whether the phosphorylation of HDAC5 by
AMPK also regulates myogenin expression.
AMPK contains two catalytic subunit isoforms, ␣1 and ␣2.
To further test whether this regulation is in an isoform-specific
manner, we separated primary myoblasts from WT, AMPK␣1

AJP-Cell Physiol • doi:10.1152/ajpcell.00124.2013 • www.ajpcell.org
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KO mice, and AMPK␣2 KO mice and induced fusion.
AMPK␣1 KO but not AMPK␣2 KO (data not shown) dramatically reduced myotube formation. A reduced myogenin level
was found in AMPK␣1 KO muscle compared with WT muscle. In addition, overexpression of HDAC5 mutants abolished
the effect AMPK␣1 knockdown on myogenin expression,
myogenin promoter activity, and myogenesis in C2C12 cells.
Furthermore, mutation of either HDAC5 Ser 259 or Ser 498
abolished the regulatory effects of AMPK␣1 on myogenin in
C2C12 cells, indicating that the phosphorylations of both Ser
259 and Ser 498 by AMPK␣1 might be required for the
efficient nuclear export of HDAC5.
Because RNA interference only partially knockdown AMPK
catalytic ␣-subunit, to clearly elucidate the role of AMPK␣1
on myogenin expression, we isolated primary myoblasts from
neonatal WT and AMPK␣1 KO mice, and these myoblasts
were transfected with myogenin promoter-luciferase vector or
with HDAC5 WT or HDAC5 mutants (Ser 259 and Ser 498 to
Ala). HDAC5 WT dramatically suppressed myogenin promoter activity in AMPK␣1 KO compared with WT primary
myoblasts, showing that the absence of AMPK␣1 activity
attenuates the inhibitory effect on HDAC5. These mutants
(Ser259Ala, Ser498Ala, and DM) suppressed myogenin promoter activity in both AMPK␣1 KO and WT myoblasts to a
similar extent, showing that these sites are necessary for
induction of HDAC5 translocation by AMPK␣1.
Our observation that AMPK activity is necessary to promote
myogenin expression and myogenesis via phosphorylation of
HDAC5 has important physiological implications. The obesity
epidemic is becoming increasingly serious, and it is well
demonstrated that obesity inhibits AMPK activity via TNF␣
(41). In addition, AMPK activity is also regulated by adipokines, such as leptin, adiponectin, and resistin, and cytokines,
such as interleukin-6 (42). Therefore, obesity, inflammation,
and other physiological factors that inhibit AMPK activity are
likely to negatively affect myogenesis through downregulation
of myogenin transcription, which may exert long-term negative
effects on the mass and properties of skeletal muscle. Indeed,
in this study, we observed that the fiber number in soleus
muscle was reduced for ⬃25% and muscle fiber diameter was
reduced for ⬃20% due to AMPK␣1 KO, and TA muscle was
found to be 30% smaller in AMPK␣1 KO mice than in WT
mice, clearly showing the importance of AMPK in the regulation of myogenesis. In addition, a reduced body weight but a
normal head-to-tail length was observed in AMPK␣1 KO,
which could be mostly due to the reduced muscle mass. Hence,
drugs activating AMPK, such as metformin, a common antidiabetic drug, can be used to activate AMPK to promote muscle
development and regeneration. In addition, the demonstration
of HDAC5 in the mediation of myogenin expression and
myogenesis facilitates the exploration of HDAC5 inhibitors as
additional chemical agents to enhance muscular development
and regeneration, improving overall muscle properties. Interestingly, AMPK␣2 KO was associated with increased muscle
fiber diameter, which could be due to the inhibitory effects of
AMPK␣2 on protein synthesis suggesting that AMPK␣1 and
AMPK␣2 have different roles in myogenesis and muscle
hypertrophy (5).
In summary, AMPK phosphorylates HDAC5, which promotes the expression of myogenin and myogenesis. These data
in combination with our previous observation in the regulation

of ␤-catenin expression by HDAC5 (48) bring a uniform
mechanisms linking AMPK to myogenesis through phosphorylation of HDAC5, a notion corroborated by the wide presence
of MEF2 binding sites in the promoters of myogenic genes.
Furthermore, in this study, we demonstrate that such promoting
effect on myogenesis is mainly mediated by AMPK␣1 subunit.
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